logo
Oswal Pumps IPO: GMP, subscription status, other key details. Apply or not?

Oswal Pumps IPO: GMP, subscription status, other key details. Apply or not?

Mint15 hours ago

Oswal Pumps IPO: The initial public offering (IPO) of pump manufacturer and distributor, Oswal Pumps Ltd, was launched on Friday and received decent demand from investors. Oswal Pumps IPO is a mainboard IPO.
The three-day subscription period of Oswal Pumps IPO began on June 13 and will end on June 17. Oswal Pumps IPO allotment date will likely be June 18, and the IPO listing date is expected to be June 20. The equity shares of the company will be listed on both the stock exchanges - BSE and NSE.
The company plans to raise ₹ 1,387.34 crore from the public issue, which is a combination of fresh issue of 1.45 crore equity shares worth ₹ 890 crore, and an offer-for-sale (OFS) component of 81 lakh shares amounting to ₹ 497.34 crore.
Oswal Pumps IPO price band is set at ₹ 584 to ₹ 614 per share. The IPO lot size is 24 shares, and the minimum investment amount required by retail investors is ₹ 14,016.
IIFL Capital Services, Axis Capital, CLSA India, JM Financial, Nuvama Wealth Management are the book running lead managers of the Oswal Pumps IPO, while MUFG Intime India (Link Intime) is the IPO registrar. Oswal Pumps IPO
Here's a look at Oswal Pumps IPO GMO, subscription status, review, other details:
Oswal Pumps IPO has been subscribed 42% so far. The public issue received bids for 67.83 lakh equity shares as against 1.62 crore shares on offer, according to data on NSE as on Friday, June 13, the first day of the bidding process.
The retail portion was subscribed 45%, while the Non Institutional Investors (NII) category was booked 79%. The Qualified Institutional Buyers (QIBs) portion received 8% subscription so far.
Oswal Pumps shares are showing a muted trend in the grey market premium (GMP). According to stock market experts, Oswal Pumps IPO GMP today is ₹ 40 per share. This indicates that Oswal Pumps shares are trading at ₹ 654 apiece in the grey market, which is at a premium of 6.51% to the issue price of ₹ 614 per share.
Oswal Pumps is the fastest growing vertically integrated solar pump manufacturer in India, in terms of revenue growth between FY22-FY24. The company has delivered robust Revenue, EBITDA and PAT CAGR of 44%,103% and 134% between FY22-9MFY25 respectively. It currently has an order book of ₹ 1,100 crore and an additional bid pipeline of ₹ 3,200 crore indicating decent growth visibility in the coming years.
'At the upper price band of ₹ 614, on post issue capital basis, the IPO is valued at 9MFY25 annualized P/E and EV/EBITDA multiple of 24.2x and 16.4x respectively, which is at a discount to its closest peer Shakti Pumps. We recommend 'Subscribe' to the issue,' said Nirmal Bang.
Rajan Shinde, Research Analyst, Mehta Equities believes Oswal Pumps IPO brings investors an opportunity to invest in a high-growth, vertically integrated player in the solar pump manufacturing space.
'On valuation parse on upper price band of ₹ 614, the issue is asking a market cap of ₹ 6,998 crore. Based on annualized FY25 annualised earnings and fully diluted post-IPO paid up capital, the company is asking for a PE 24.2x which we feel reasonable relative to industry peers which are trading at an average of 42x,' Shinde said.
As one of the largest suppliers of solar-powered agricultural pumps under the PM-KUSUM scheme, he believes the company is well positioned to benefit from policy tailwinds and the accelerating shift toward sustainable irrigation solutions.
Hence, Shinde recommends investors to subscribe to the Oswal Pumps IPO for long-term perspective.
Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before making any investment decisions.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Lemon Tree Hotels signs new property in Arunachal Pradesh
Lemon Tree Hotels signs new property in Arunachal Pradesh

Business Standard

time9 hours ago

  • Business Standard

Lemon Tree Hotels signs new property in Arunachal Pradesh

Lemon Tree Hotels has announced the signing of a new property in Itanagar, Arunachal Pradesh. The property will be managed by Carnation Hotels, a wholly owned subsidiary of Lemon Tree Hotels. Lemon Tree Hotel, Itanagar will feature 70 well-appointed rooms, a restaurant, a bar, a banquet hall, a meeting room, a swimming pool, a gym, a spa, and other public areas. Donyi Polo Airport, Itanagar, is approximately 25 km from the property, while Naharlagun (Itanagar) Railway Station is around 12 km away. The hotel is also well-connected by road, offering easy access to both public and private transportation. Lemon Tree Hotels (LTHL) is one of the largest hotel chains in India and owns/leases/operates/franchises hotels across the upscale, upper-midscale, midscale, and economy segments. The group offers seven brands to meet guests needs across all levels, viz., Aurika Hotels & Resorts, Lemon Tree Premier, Lemon Tree Hotels, Red Fox Hotels by Lemon Tree Hotels, Keys Prima by Lemon Tree Hotels, Keys Select by Lemon Tree Hotels, and Keys Lite by Lemon Tree Hotels. Lemon Tree Hotels reported a 26.37% jump in consolidated net profit to Rs 84.64 crore, while revenue from operations rose 15.64% to Rs 378.51 crore in Q4 March 2025 over Q4 March 2024. The scrip rose 0.51% to end at Rs 138.55 on the BSE on Friday.

Syngene's Bengaluru-based facility gets 'NAi' status from US FDA
Syngene's Bengaluru-based facility gets 'NAi' status from US FDA

Business Standard

time11 hours ago

  • Business Standard

Syngene's Bengaluru-based facility gets 'NAi' status from US FDA

Syngene International said that the United States Food and Drug Administration (US FDA) conducted a good clinical practices (GCP) compliance inspection of the company's facility located at Semicon Park, Bengaluru, from 09 to 13 of June 2025. The inspection concluded successfully, with the facility found to be in compliance with the required regulations. The inspection resulted in zero observations and no Form 483 was issued. The inspection has been classified as no action indicated (NAI). The company remains commitment to high operating standards and rigorous compliance with global regulatory requirements across all its operations, Syngene said in a statement. Syngene International is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. On a consolidated basis, net profit of Syngene International declined 2.81% to Rs 183.30 crore while net sales rose 11.03% to Rs 1018 crore in Q4 March 2025 over Q4 March 2024. The scrip had lost 1.57% to end at Rs 652.50 on the BSE on Friday.

NATCO Pharma's Hyderabad-based plant gets 'one' Form 483 observation post US FDA audit
NATCO Pharma's Hyderabad-based plant gets 'one' Form 483 observation post US FDA audit

Business Standard

time11 hours ago

  • Business Standard

NATCO Pharma's Hyderabad-based plant gets 'one' Form 483 observation post US FDA audit

NATCO Pharma said that the U.S. Food and Drug Administration (FDA) had conducted an inspection at the API manufacturing plant located in Mekaguda, Hyderabad, India, which was conducted from 09 to 13 of June 2025. On conclusion of the inspection, the company received one observation in the Form-483. The company believes that the observation is procedural in nature. The company is confident to address this observation comprehensively. NATCO Pharma, headquartered at Hyderabad, India, develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients and crop protection products. The companys consolidated net profit increased 5.3% to Rs 406.60 crore on 14.3% jump in revenue from operations to Rs 1,221 crore in Q4 FY25 over Q4 FY24. The scrip had declined 1.26% to end at Rs 912.55 on the BSE on Friday.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store